NCT01562847View on ClinicalTrials.gov

Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib

UnknownOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2015

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Nilotinib

Patients will be treated with 800 mg nilotinib daily.

Trial Locations (1)

137-701

Seoul St. Mary's Hospital, Seoul

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Seoul St. Mary's Hospital

OTHER